- Home
- SANG vs IPHA Comparison
SANG vs IPHA Comparison
Compare SANG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANG | IPHA |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SANG | IPHA |
|---|---|---|
| Price | $4.98 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 3.7K | ★ 27.0K |
| Earning Date | 02-04-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,360,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | $4.59 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $1.60 |
| 52 Week High | $7.99 | $2.63 |
Technical Indicators
Market Signals| Indicator | SANG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 47.30 |
| Support Level | $4.86 | $1.63 |
| Resistance Level | $5.08 | $1.83 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 45.53 | 51.61 |
Price Performance
Historical ComparisonAbout SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.